Clinical Trial Update: A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for PRS-344/S095012 (PD-L1x4-1BB bispecific antibody-anticalin fusion) in solid tumors; the Phase 1/Phase 2 study sponsored by Servier Bio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• PRS-344/S095012 (PD-L1x4-1BB bispecific antibody-anticalin fusion)

Snippet

Sponsor: Servier Bio-Innovation LLC | Conditions: Solid Tumor | Phase 1, Phase 2 | Status: COMPLETED